Cellid Submits Phase 1 Clinical Trial Application for Anti-Cancer Immunotherapy Vaccine
[Asia Economy Reporter Minji Lee] Cellid announced on the 18th that it has applied to the Ministry of Food and Drug Safety for an open-label Phase 1 clinical trial plan to explore the tolerability, safety, and efficacy of BVAC-M, an anticancer immunotherapy vaccine for patients with metastatic or recurrent melanoma.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- 1,224th Lotto First Prize: '9, 18, 21, 27, 44, 45'... 2.4 Billion Won Jackpot
- Woman in Her 50s Found Dead 28 Days After Going Missing on Bukhansan Mountain
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
The company stated, "BVAC-M continuously expresses each antigen protein through the GP100 and MAGE-A3 cancer antigen genes, generating antibodies, and activates various immune cells in the patient's body, such as T cells, B cells, and natural killer cells, inducing a complex anticancer immune response. It is expected to help treat patients who do not benefit from existing anticancer therapies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
